<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Exendin-4 is a GLP-1 agonist that is clinically used for the treatment of <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and may also have neuroprotective effect </plain></SENT>
<SENT sid="1" pm="."><plain>We explored the effect of repeated administration of exendin-4 (0.5 Î¼g/kg, intraperitoneal twice a day for 7 days) on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, neurological deficit (neurological score, grip test, foot fault and rota rod tests), <z:mp ids='MP_0003674'>oxidative stress</z:mp> parameters (malondialdehyde, reduced <z:chebi fb="0" ids="16856">glutathione</z:chebi>, and <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase) and expression of endothelin (ET) ET(A) and ET(B) receptors following <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> produced in rats by permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="2" pm="."><plain>Since ET(A) receptors in the central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) are involved in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, we determined the effect of a specific ET(A) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, BQ123 (1mg/kg, intravenously administered thrice: 30 min, 2h and 4h after MCAO for a total dose of 3 mg/kg) on <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in control and exendin-4 treated rats </plain></SENT>
<SENT sid="3" pm="."><plain>Results indicate that exendin-4 treated rats had significant protection following MCAO induced <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was 27% less compared to vehicle treated rats </plain></SENT>
<SENT sid="5" pm="."><plain>The neurological deficit following MCAO was lower and <z:mp ids='MP_0003674'>oxidative stress</z:mp> parameters were improved in exendin-4 treated rats compared to control </plain></SENT>
<SENT sid="6" pm="."><plain>BQ123 significantly improved <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, <z:mp ids='MP_0003674'>oxidative stress</z:mp> parameters and neurological deficit in ischemic rats treated with vehicle or exendin-4 </plain></SENT>
<SENT sid="7" pm="."><plain>BQ123 induced protection from <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was similar in vehicle or exendin-4 treated rats </plain></SENT>
<SENT sid="8" pm="."><plain>Expression of ET(A) receptors was significantly increased following <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> which was not affected by exendin-4 treatment or by BQ123 administration </plain></SENT>
<SENT sid="9" pm="."><plain>No change in expression of ET(B) receptors was observed following <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> or any treatment </plain></SENT>
<SENT sid="10" pm="."><plain>It is concluded that exendin-4 protects the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> from damage due to <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> by reducing <z:mp ids='MP_0003674'>oxidative stress</z:mp> and is independent of ET receptor involvement </plain></SENT>
</text></document>